UNLABELLED: Due to aging of the population the prevalence of both cardiovascular diseases (CVDs) and cancer is increasing. Elderly patients are often under-represented in clinical trials, resulting in limited guidance about treatment and outcome. This study gives insight into the prevalence of CVD among unselected patients with colon, rectum, lung, breast and prostate cancer and its effects on cancer treatment and outcome. Over one fourth (N=11,200) of all included cancer patients aged 50 or older (N=41,126) also suffered from CVD, especially those with lung (34%) or colon cancer (30%). These patients were often treated less aggressively, especially in case COPD or diabetes was also present. CVD had an independent prognostic effect among patients with colon, rectum and prostate cancer. This prognostic effect could not be fully explained by differences in treatment. CONCLUSIONS: Many cancer patients with severe CVD have a poorer prognosis. More research is needed for explaining the underlying factors for the decreased survival. Such research should lead to treatment guidelines for these patients.
UNLABELLED: Due to aging of the population the prevalence of both cardiovascular diseases (CVDs) and cancer is increasing. Elderly patients are often under-represented in clinical trials, resulting in limited guidance about treatment and outcome. This study gives insight into the prevalence of CVD among unselected patients with colon, rectum, lung, breast and prostate cancer and its effects on cancer treatment and outcome. Over one fourth (N=11,200) of all included cancerpatients aged 50 or older (N=41,126) also suffered from CVD, especially those with lung (34%) or colon cancer (30%). These patients were often treated less aggressively, especially in case COPD or diabetes was also present. CVD had an independent prognostic effect among patients with colon, rectum and prostate cancer. This prognostic effect could not be fully explained by differences in treatment. CONCLUSIONS: Many cancerpatients with severe CVD have a poorer prognosis. More research is needed for explaining the underlying factors for the decreased survival. Such research should lead to treatment guidelines for these patients.
Authors: Joseph C Kong; Oliver Peacock; Peadar S Waters; Tim Eglinton; Satish K Warrier; Christopher Wakeman; Frank A Frizelle; Alexander G Heriot; Jacob J McCormick Journal: Langenbecks Arch Surg Date: 2020-06-12 Impact factor: 3.445
Authors: Oliver Peacock; Peadar S Waters; Joseph C Kong; Satish K Warrier; Chris Wakeman; Tim Eglinton; Declan G Murphy; Alexander G Heriot; Frank A Frizelle; Jacob J McCormick Journal: Tech Coloproctol Date: 2020-01-06 Impact factor: 3.781
Authors: Nadine J McCleary; Sui Zhang; Chao Ma; Fang-Shu Ou; Tiffany M Bainter; Alan P Venook; Donna Niedzwiecki; Heinz-Josef Lenz; Federico Innocenti; Bert H O'Neil; Blase N Polite; Howard S Hochster; James N Atkins; Richard M Goldberg; Kimmie Ng; Robert J Mayer; Charles D Blanke; Eileen M O'Reilly; Charles S Fuchs; Jeffrey A Meyerhardt Journal: J Geriatr Oncol Date: 2022-01-31 Impact factor: 3.929
Authors: Dounya Schoormans; Pauline A J Vissers; Myrthe P P van Herk-Sukel; Johan Denollet; Susanne S Pedersen; Susanne O Dalton; Nina Rottmann; Lonneke van de Poll-Franse Journal: Cancer Med Date: 2018-09-15 Impact factor: 4.452
Authors: Sorrel Burden; Debra J Jones; Jana Sremanakova; Anne Marie Sowerbutts; Simon Lal; Mark Pilling; Chris Todd Journal: Cochrane Database Syst Rev Date: 2019-11-22